Wegovy is the brand name for
semaglutide dosed specifically for weight management — it's the version of this GLP-1 medication that carries a dedicated FDA approval for chronic weight loss in adults with obesity, or who are overweight with a related health condition. That distinguishes it from
Ozempic, which contains the same active ingredient but is approved only for type 2 diabetes.
Wegovy has also picked up two additional FDA approvals beyond weight management: reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established heart disease who are overweight or living with obesity, and treating a liver condition called MASH (metabolic dysfunction-associated steatohepatitis).